AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In the closing of the recent trading day, Astrazeneca (AZN) stood at $80.21, denoting a +0.24% change from the preceding trading day.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.

AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

ASML Hld

LVMH Moet Hennessy Louis Vuitton

Novo Nordisk

SAP SE

Five mega companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks make this list.

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations. The Food and Drug Ad.

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

Caterpillar

Coca-Cola

Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism.

The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now

Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.

Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN). AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic, Eclipse Ventures, Fox Chase Cancer Center, Echo Global Granger Management Mercy Health, and the University of Missouri as Nucleus expands devel.

Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment

In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then.

Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

Reaction to AstraZeneca PLC (LSE:AZN)'s presentations at the annual American Society of Clinical Oncology conference was broadly positive following of sessions with analysts and clinicians. Eye-catching was the claim around Tagrisso, which was hailed as "practice changing" when administered to lung cancer with a certain mutation of the disease.

AstraZeneca: ASCO feedback positive

In the latest trading session, Astrazeneca (AZN) closed at $78.99, marking a +1.24% move from the previous day.

Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know

Amgen

Viking Therapeutics

Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CR.

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT). These results will be present.

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as I.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy.

ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

AbbVie

Vertex Pharmaceuticals

AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.

3 No-Brainer Stocks to Buy in June

Compugen

Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipeline Compugen to receive $5 million milestone payment from AstraZeneca HOLON, Israel , May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody.

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AstraZeneca has been a top-performing stock since 2014. Management recently rolled out an $80 billion sales target for 2030.

This Pharma Stock Is Poised to Keep Outperforming the S&P 500

GlaxoSmithKline

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.

AstraZeneca started at buy at Goldman, which rates GSK a neutral

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious.

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

AstraZeneca just wrapped up its last strategic plan successfully. It's now setting a new ambition to be completed by 2030.

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

CAMBRIDGE, England--(BUSINESS WIRE)--Dato-DXd TL01 OS HLR.

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical sign.

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

News for AstraZeneca Stock (AZN)